Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Analyst Ratings Changes
Several equities analysts have recently weighed in on EBS shares. Cantor Fitzgerald lowered Emergent BioSolutions from an "overweight" rating to a "neutral" rating in a research note on Friday, April 29th. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Saturday, May 7th. Cowen reduced their price objective on Emergent BioSolutions from $40.00 to $30.00 in a research note on Friday, April 29th. Chardan Capital reduced their price target on Emergent BioSolutions from $75.00 to $65.00 in a research report on Friday, April 29th. Finally, Cowen reduced their price target on Emergent BioSolutions from $40.00 to $30.00 in a research report on Friday, April 29th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $49.17.
Emergent BioSolutions Stock Up 2.0 %
Shares of EBS traded up $0.61 during trading on Friday, reaching $30.50. The company's stock had a trading volume of 1,130,178 shares, compared to its average volume of 670,304. The company has a fifty day moving average of $31.39 and a two-hundred day moving average of $36.67. Emergent BioSolutions has a twelve month low of $26.85 and a twelve month high of $65.09. The company has a market cap of $1.52 billion, a price-to-earnings ratio of 17.69 and a beta of 0.98. The company has a quick ratio of 2.38, a current ratio of 3.92 and a debt-to-equity ratio of 0.52.
Emergent BioSolutions (NYSE:EBS - Get Rating) last announced its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($1.24). Emergent BioSolutions had a net margin of 6.02% and a return on equity of 12.22%. The business had revenue of $242.70 million during the quarter, compared to analyst estimates of $268.77 million. During the same period in the previous year, the company earned $0.33 earnings per share. The business's revenue for the quarter was down 38.9% on a year-over-year basis. On average, sell-side analysts predict that Emergent BioSolutions will post -0.7 EPS for the current fiscal year.
Insider Buying and Selling at Emergent BioSolutions
In other Emergent BioSolutions news, Director Kathryn C. Zoon sold 1,173 shares of the company's stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $31.52, for a total value of $36,972.96. Following the transaction, the director now directly owns 19,654 shares of the company's stock, valued at approximately $619,494.08. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Kathryn C. Zoon sold 1,173 shares of the business's stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $31.52, for a total value of $36,972.96. Following the completion of the sale, the director now directly owns 19,654 shares in the company, valued at approximately $619,494.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kathryn C. Zoon sold 1,996 shares of the business's stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $35.53, for a total value of $70,917.88. Following the completion of the sale, the director now owns 12,381 shares of the company's stock, valued at $439,896.93. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.
